Rheumatoid Arthritis (RA) - Epidemiology Forecast

List of Tables

Rheumatoid Arthritis Insights and Trends

Rheumatoid arthritis causes joint inflammation and pain. It happens when the immune system does not work properly and attacks the lining of the joints, called the synovium. The disease commonly affects the hands, knees or ankles, and usually the same joint on both sides of the body, such as both hands or both knees. But sometimes rheumatoid arthritis causes problems in other parts of the body as well, such as the eyes, heart and circulatory system and/or the lungs.
In rheumatoid arthritis, an autoimmune disease, the immune system mistakenly attacks the synovium the lining of joints causing inflammation, thickening, pain, swelling, and reduced movement; while the exact cause is unclear, it is thought to involve genetic susceptibility triggered by environmental factors such as infections or stress.
Rheumatoid arthritis is more common in women and about 75% of rheumatoid arthritis patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, rheumatoid arthritis can start at any age.
Typically, rheumatoid arthritis is diagnosed by a combination of patient's symptoms, results of doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.
More than two thirds of rheumatoid arthritis patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.

DelveInsight's 'Rheumatoid Arthritis - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Rheumatoid Arthritis Understanding and Diagnosis

Rheumatoid Arthritis Overview

Rheumatoid arthritis is a chronic systemic inflammatory autoimmune disease of unknown cause, typically presenting as bilateral, symmetric polyarthritis of the hands and feet, though any synovial joint and extra-articular organs such as the skin, heart, lungs, and eyes may be involved. It is believed to arise in genetically predisposed individuals (e.g., HLA-DR4/DR1 carriers) following environmental triggers like smoking or infection, leading to an autoimmune response. Although no single test is definitive, diagnosis relies on clinical evaluation and supportive findings such as inflammatory markers (ESR, CRP) and autoantibodies including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), with imaging (X-ray, ultrasound, MRI) used to assess joint damage and disease progression.

Rheumatoid Arthritis Epidemiology

Key Findings from Rheumatoid Arthritis Epidemiological Analysis and Forecast

As per Xu et al. (2021), in the US, approximately 1.3 million adults suffer from rheumatoid arthritis, representing 0.6% to 1% of the adult population.
As per Stanciu et al. (2022), the estimated prevalence for rheumatoid arthritis in the adults is around 0.81%, with a higher prevalence for women (1.16%) than for men (0.44%) in the UK.
According to the World Health Organization (2023), about 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years of age.
As per Jinno et al. (2019) and Bergstra et al. (2018), the targeted therapies usage varies from 18% to 50% in Japan, which is similar to the usage of targeted therapies in the US.
Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age standardized prevalence rate have increased over the same period, and the number of cases is projected to continue to increase.
While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of rheumatoid arthritis, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Rheumatoid Arthritis Patient Population Forecast

Report Key Strengths

Epidemiology-based (epi-based) Bottom-up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs:

What are the disease risks, burdens, and unmet needs of glioma? What will be the growth opportunities across the 7MM concerning the patient population with glioma?
What is the historical and forecasted glioma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI0340

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Forecast Flow Methodology

5. Disease Background and Overview

5.1. Introduction
5.2. Stages of Rheumatoid Arthritis
5.3. Types of Rheumatoid Arthritis
- 5.3.1. Seropositive Rheumatoid Arthritis
- 5.3.2. Seronegative Rheumatoid Arthritis
5.4. Signs and Symptoms of Rheumatoid Arthritis
5.5. Risk Factors and Causes of Rheumatoid Arthritis
5.6. Complications of Rheumatoid Arthritis
5.7. Pathogenesis of Rheumatoid Arthritis
- 5.7.1. Disease Initiation
- 5.7.2. Triggers of Disease
- 5.7.3. Citrullination
- 5.7.4. Early and Established Rheumatoid Arthritis
- 5.7.5. Propagation of Disease
5.8. Diagnosis of Rheumatoid Arthritis
5.9. Screening of Rheumatoid Arthritis

6. Epidemiology and Patient Population of 7MM

6.1. Epidemiology Methodology
6.2. Key Findings
6.3. Assumptions and Rationale: 7MM
6.4. Epidemiology Scenario: 7MM
- 6.4.1. Total Prevalent Cases of Rheumatoid Arthritis in the 7MM
- 6.4.2. Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
- 6.4.3. Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
- 6.4.4. Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
- 6.4.5. Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the7MM
6.5. The United States Epidemiology
- 6.5.1. Total Prevalent Cases of Rheumatoid Arthritis in the United States
- 6.5.2. Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
- 6.5.3. Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
- 6.5.4. Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
- 6.5.5. Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
6.6. EU4 and the UK Epidemiology
- 6.6.1. Total Prevalent Population of Rheumatoid Arthritis in EU4 and the UK
- 6.6.2. Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
- 6.6.3. Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
- 6.6.4. Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
- 6.6.5. Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
6.7. Japan Epidemiology
- 6.7.1. Total Prevalent Cases of Rheumatoid Arthritis in Japan
- 6.7.2. Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
- 6.7.3. Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
- 6.7.4. Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
- 6.7.5. Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan

7. KOL Views

8. Appendix

8.1. Bibliography
8.2. Report Methodology

9. Delveinsight Capabilities

10. Disclaimer

11. About DelveInsight

Product Code: DIEI0340

List of Tables

Table 1: Summary of RA Epidemiology (2022-2036)
Table 2: Total Prevalent Cases of RA in the 7MM (2022-2036)
Table 3: Total Diagnosed Prevalent Cases of RA in the 7MM (2022-2036)
Table 4: Gender-specific Prevalent Cases of RA in the 7MM (2022-2036)
Table 5: Age-specific Prevalent Cases of RA in the 7MM (2022-2036)
Table 6: Severity-specific Prevalent Cases of RA in the 7MM (2022-2036)
Table 7: Patients on targeted therapies of RA in the 7MM (2022-2036)
Table 8: Line-Wise Treated Cases of RA in the 7MM (2022-2036)
Table 9: Total Prevalent Cases of RA in the United States (2022-2036)
Table 10: Total Diagnosed Prevalent Cases of RA in the United States (2022-2036)
Table 11: Gender-specific Prevalent Cases of RA in the United States (2022-2036)
Table 12: Age-specific Prevalent Cases of RA in the United States (2022-2036)
Table 13: Severity-specific Prevalent Cases of RA in the United States (2022-2036)
Table 14: Patients on targeted therapies of RA in the United States (2022-2036)
Table 15: Line-Wise Treated Cases of RA in the United States (2022-2036)
Table 16: Total Prevalent Population of RA in EU4 and the UK (2022-2036)
Table 17: Total of Diagnosed Prevalent Cases of RA in EU4 and the UK (2022-2036)
Table 18: Gender-specific Prevalence of RA in EU4 and the UK (2022-2036)
Table 19: Age-specific Prevalence of RA in EU4 and the UK (2022-2036)
Table 20: Severity-specific Prevalent Cases of RA in EU4 and the UK (2022-2036)
Table 21: Patients on targeted therapies of RA in EU4 and the UK (2022-2036)
Table 22: Line-Wise Treated Cases of RA in EU4 and the UK (2022-2036)
Table 23: Total Prevalent Cases of RA in Japan (2022-2036)
Table 24: Total Diagnosed Prevalent Cases of RA in Japan (2022-2036)
Table 25: Gender-specific Prevalent Cases of RA in Japan (2022-2036)
Table 26: Age-specific Prevalent Cases of RA in Japan (2022-2036)
Table 27: Severity-specific Prevalent Cases of RA in Japan (2022-2036)
Table 28: Patients on targeted therapies of RA in Japan (2022-2036)
Table 29: Line-Wise Treated Cases of RA in Japan (2022-2036)

List of Figures

Figure 1: RA Distressed Area
Figure 2: Bone joint differentiation of normal and RA
Figure 3: Development and progression of RA
Figure 4: Sign and Symptoms of RA
Figure 5: Associations and links for RA
Figure 6: Initiation and Progression of RA
Figure 7: Clinical manifestations of RA
Figure 8: Antinuclear Antibody Test
Figure 9: Clinical Diagnosis of RA
Figure 10: Diagnostic criteria for RA
Figure 11: Screening for Rheumatoid Arthritis
Figure 12: Total Prevalent Cases of RA in the 7MM (2022-2036)
Figure 13: Total Diagnosed Prevalent Cases of RA in the 7MM (2022-2036)
Figure 14: Gender-specific Prevalent Cases of RA in the 7MM (2022-2036)
Figure 15: Age-specific Prevalent Cases of RA in the 7MM (2022-2036)
Figure 16: Severity-specific Prevalent Cases of RA in the 7MM (2022-2036)
Figure 17: Patients on targeted therapies of RA in the 7MM (2022-2036)
Figure 18: Line-Wise Treated Cases of RA in the 7MM (2022-2036)
Figure 19: Total Prevalent Cases of RA in the United States (2022-2036)
Figure 20: Total Diagnosed Prevalent Cases of RA in the United States (2022-2036)
Figure 21: Gender-specific Prevalent Cases of RA in the United States (2022-2036)
Figure 22: Age-specific Prevalent Cases of RA in the United States (2022-2036)
Figure 23: Severity-specific Prevalent Cases of RA in the United States (2022-2036)
Figure 24: Patients on targeted therapies of RA in the United States (2022-2036)
Figure 25: Line-Wise Treated Cases of RA in the United States (2022-2036)
Figure 26: Total Prevalent Cases of RA in EU4 and the UK (2022-2036)
Figure 27: Total Diagnosed Prevalent Cases of RA in EU4 and the UK (2022-2036)
Figure 28: Gender-specific Prevalent Cases of RA in EU4 and the UK (2022-2036)
Figure 29: Age-specific Prevalent Cases of RA in EU4 and the UK (2022-2036)
Figure 30: Severity-specific Prevalent Cases of RA in EU4 and the UK (2022-2036)
Figure 31: Patients on targeted therapies of RA in EU4 and the UK (2022-2036)
Figure 32: Line-Wise Treated Cases of RA in EU4 and the UK (2022-2036)
Figure 33: Total Prevalent Cases of RA in Japan (2022-2036)
Figure 34: Total Diagnosed Prevalent Cases of RA in Japan (2022-2036)
Figure 35: Gender-specific Prevalent Cases of RA in Japan (2022-2036)
Figure 36: Age-specific Prevalent Cases of RA in Japan (2022-2036)
Figure 37: Severity-specific Prevalent Cases of RA in Japan (2022-2036)
Figure 38: Patients on targeted therapies of RA in Japan (2022-2036)
Figure 39: Line-Wise Treated Cases of RA in Japan (2022-2036)

Rheumatoid Arthritis (RA) - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Rheumatoid Arthritis Insights and Trends

Rheumatoid Arthritis Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Forecast Flow Methodology

5. Disease Background and Overview

6. Epidemiology and Patient Population of 7MM

7. KOL Views

8. Appendix

9. Delveinsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

List of Figures